Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Doses of the US Yellow Fever Vaccine
NCT05374317Phase 4Completed
- Sponsor
- U.S. Army Medical Research Institute of Infectious Diseases
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of 17D yellow fever vaccine in yellow fever (3 arms), sponsored by U.S. Army Medical Research Institute of Infectious Diseases. Primary endpoints: Adverse Events at 28 days and Neutralizing Antibody Response at 28 days. Started Jun 2021; status: completed.
02
Drugs
17D yellow fever vaccine
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT05374317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374317.